

# **Supplemental Material**

**Table S1. Major Resources.**

**Cultured Cells**

| <b>Name</b> | <b>Vendor or Source</b> | <b>Sex (F, M, or unknown)</b> | <b>Persistent ID / URL</b>                                                                                |
|-------------|-------------------------|-------------------------------|-----------------------------------------------------------------------------------------------------------|
| J774A.1     | ATCC® TIB-67™           | F                             | <a href="https://www.atcc.org/products/all/TIB-67.aspx">https://www.atcc.org/products/all/TIB-67.aspx</a> |

**Table S2. Comparison of Baseline Characteristics between overall DEFINE study and current substudy comparing placebo group vs. anacetrapib group.**

|                                               | DEFINE<br>study<br>Placebo<br>(N = 812) | Substudy<br>Placebo<br>(N = 289) | DEFINE<br>study<br>Anacetrapib<br>(N = 811) | Substudy<br>Anacetrapib<br>(N = 285) |
|-----------------------------------------------|-----------------------------------------|----------------------------------|---------------------------------------------|--------------------------------------|
| Age, years, mean (SD)*                        | 62.9 (9.0)                              | 62.4 (9.1)                       | 62.5 (8.7)                                  | 61.5 (9.1)                           |
| Females                                       | 194 (23.9)                              | 132 (46)                         | 182 (22.4)                                  | 99 (35)                              |
| White race                                    | 669 (82.4)                              | 223 (77)                         | 686 (84.6)                                  | 226 (79)                             |
| Body Mass Index kg/m <sup>2</sup> , mean (SD) | 30.1 (5.2)                              | 30.5 (5.4)                       | 30.4 (5.5)                                  | 30.4 (5.6)                           |
| Diabetes Mellitus                             | 432 (53.2)                              | 188 (65)                         | 430 (53.0)                                  | 171 (60)                             |
| Atorvastatin                                  | 275 (33.9)                              | 97 (33.6)                        | 276 (34.0)                                  | 101 (35.4)                           |
| Simvastatin                                   | 372 (45.8)                              | 132 (45.7)                       | 367 (45.3)                                  | 95 (33.3)                            |
| Rosuvastatin                                  | 86 (10.6)                               | 49 (17.0)                        | 104 (12.8)                                  | 62 (21.8)                            |
| Other statin†                                 | 72 (8.9)                                | 10 (3.5)                         | 60 (7.4)                                    | 26 (9.1)                             |

\*Values are presented as N (%) unless otherwise stated. †Other statin includes pravastatin and lovastatin.

Figure S1. Substudy Design




Diagram of participants included in substudy.